Now, new findings from researchers at Stanford Medicine are available on a rare side effect that has been closely watched since the introduction of mRNA COVID-19 vaccines: myocarditis, or inflammation of the heart muscle.
This reaction is not something that the study suggests is common. It also doesn’t change the broader understanding that mRNA COVID-19 vaccines have helped protect millions of people. Instead, the research attempts to answer a more specific question:
Why do a very small number of people develop myocarditis after vaccination, particularly younger males?
That question has mattered to doctors, scientists and families because even rare side effects merit careful study. Understanding what causes them may help make future vaccines and treatments even safer.
Myocarditis following mRNA vaccination is still rare. Stanford Medicine noted that health experts have repeatedly said that health risks, including heart-related risks, are generally more common and more serious after infection than after vaccination, with COVID-19 infection itself also capable of causing myocarditis.
But researchers wanted to learn more about what happens in the rare cases that do occur.
In the Stanford study, researchers analysed blood samples from people who developed myocarditis after vaccination, and compared them with blood samples from vaccinated people who did not develop the condition. Two immune signalling proteins emerged: CXCL10 and interferon-gamma, or IFN-gamma.
They are proteins that belong to the normal communication network of the immune system. Cells of the immune system use them to fight threats like infections. But sometimes, very rarely, the immune response can be too strong or it can be misdirected.
The Stanford team found that levels of CXCL10 and IFN-gamma were higher in those who developed myocarditis. Researchers believe the proteins might work in tandem in a two-step immune response that can cause inflammation around heart tissue.
Scientists used lab models, studies in mice and human heart tissue grown in the lab to investigate further. With these models researchers could see how immune signals could impact heart cells.
In the study, a certain immune cell called macrophages made more CXCL10. That signal then seemed to interact with T cells, which boosted IFN-gamma activity. These immune signals appeared to work in concert to ramp up inflammation.
In experimental models, this inflammation was associated with signs of heart stress and injury, including increased levels of troponin. A protein called troponin is often checked by doctors when looking for heart muscle damage.
The researchers also used tiny models of heart tissue grown in the lab, sometimes called cardiac spheroids, to observe how heart function was affected by inflammatory signals. In those models, the inflammation seemed to interfere with normal contraction. Researchers blocked CXCL10 and IFN-gamma signalling to mitigate some of the inflammatory effects.
That doesn’t mean a new treatment for vaccine-related myocarditis is available right now. The results are mostly laboratory and preclinical to date. Doctors would need human clinical studies to use this information in treatment decisions.
The study also examined genistein, a naturally-occurring compound found in soy. Genistein has shown anti-inflammatory effects in the lab, and appeared to reduce some markers of heart stress in experimental models.
But this is an important point: the study doesn’t suggest that people should take soy supplements or eat a lot of soy to prevent or treat myocarditis.
The doses in research and conditions are not the same as normal food intake. “If you experience chest pain, shortness of breath, heart palpitations or other symptoms after vaccination or infection, you should seek medical care instead of attempting home treatments.”
The research also could help scientists understand why there have been more reports of myocarditis after vaccination in adolescent and young adult males. Research is ongoing into a number of possibilities, including hormones, genetics, immune response differences and inflammatory signalling. None of these explanations has been fully proven so far.
Myocarditis associated with the mRNA vaccine has been mild to moderate in most people and many patients recover with rest, monitoring and supportive care. But every case still matters, especially if it’s the heart.
Hence the usefulness of research like this .
This shows that vaccine safety monitoring does not stop after a vaccine is approved. And scientists continue to study rare events, looking for patterns and seeking to reduce risk while maintaining the benefits of vaccination.
The findings could also have implications beyond COVID-19. mRNA technology is being investigated for other vaccines, and medical treatments. Understanding the immune response in rare cases will help improve mRNA-based medicines in the future.
The trick is to strike a balance.
mRNA vaccines are still under wide investigation and have been used all over the world. “Rare side effects, like myocarditis, need to be taken seriously, but they also need to be put in context. Research is not to create fear. It is about better knowledge, safety and patient care.
For those with questions about vaccination, the best course of action is to consult a healthcare professional who is aware of their personal medical history.
For others, this study is a reminder that science does work.
Researchers continue to ask questions even after a medical tool is widely used. They search for rare problems. They play with possible explanations. They search for improved ways to prevent and control complications.
That careful process is what allows medicine to get better over time.”